Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614277 | 0.78 | CYP2D6 (0.39) | PRMT5WDR77CYP2D6LTA4HMCHR1 | |
| SCHEMBL4133986 | 0.78 | LTA4H (0.44) | PRMT5WDR77CYP2D6LTA4HSLC18A3 | |
| SCHEMBL7366724 | 0.76 | MAP3K14 (0.59) | MAP3K14CYP2D6HTR1ASLC6A4HRH3 | |
| SCHEMBL4751498 | 0.76 | MAP3K14 (0.59) | MAP3K14CYP2D6HTR1ASLC6A4 | |
| SCHEMBL4349140 | 0.76 | CYP2D6 (0.37) | PRMT5WDR77CYP2D6LTA4HMCHR1 | |
| SCHEMBL4349132 | 0.76 | CYP2D6 (0.37) | PRMT5WDR77CYP2D6LTA4HMCHR1 | |
| SCHEMBL14138444 | 0.75 | PRMT5 (0.46) | PRMT5WDR77CYP2D6HTR1ASLC6A4 | |
| SCHEMBL19646975 | 0.72 | MAP3K14 (0.55) | MAP3K14CYP2D6HTR1ASLC6A4 | |
| SCHEMBL5950940 | 0.72 | SMN1; SMN2 (0.47) | CYP2D6HRH3 | |
| SCHEMBL5950942 | 0.72 | SMN1; SMN2 (0.47) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | MAP3K14 704/4885PRMT5 4471/4885WDR77 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.